Copyright Informa UK Limited 2008 Not for Sale or Comercial Distribution
2008
Background: MAP0004 (a proprietary formulation of dihydroergotamine mesylate [DHE]) for inhaled delivery is being developed for acute migraine treatment. Because asthma and migraine often occur as co-morbid conditions, it is considered important to study the safety of MAP0004 in a population of asthmatic adults and to confirm that the pharmacokinetics of DHE, when inhaled by asthmatic subjects, were comparable to a population of healthy
Keywords:
- Correction
- Cite
- Save
- Machine Reading By IdeaReader
22
References
0
Citations
NaN
KQI